A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Single-Center, Multiple-Dose Study to Assess the Safety and Pharmacokinetics of ZYN002 Administered as a Transdermal Gel to Healthy Subjects

Trial Profile

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Single-Center, Multiple-Dose Study to Assess the Safety and Pharmacokinetics of ZYN002 Administered as a Transdermal Gel to Healthy Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 05 Dec 2016

At a glance

  • Drugs Cannabidiol (Primary)
  • Indications Epilepsy
  • Focus Adverse reactions
  • Sponsors Zynerba Pharmaceuticals
  • Most Recent Events

    • 05 Dec 2016 According to a Zynerba Pharmaceuticals media release, results from this study reported at the 70th Annual Meeting of the American Epilepsy Society (AES).
    • 05 Dec 2016 Results published in the Zynerba Pharmaceuticals Media Release.
    • 26 Sep 2016 Status changed from recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top